WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance’s AMTAGVI™ (lifileucel) for Advanced Melanoma
WuXi Advanced Therapies announced FDA approval of its Philadelphia site for commercial manufacturing and testing of Iovance's AMTAGVI™ which received accelerated approval of its BLA on February 16.
